Perrigo affirms FY26 adjusted EPS guidance above estimates
Perrigo Company PLC says it reported better-than-expected second-quarter financial results on Aug. 5 and affirmed FY26 adjusted EPS guidance above estimates.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Pfizer (PFE) and Valneva (VALN) EMA validates Lyme vaccine MAA
EMA validates the marketing authorization application for PF-07307405, based on the Phase 3 VALOR trial in more than 9,400 participants aged five years and older, reporting more than 70% efficacy and no safety concerns.
Pfizer’s Valneva Lyme vaccine MA application validated by EMA
Pfizer (PFE) and Valneva report the European Medicines Agency validated their marketing authorization application for their Lyme disease vaccine candidate.